don't let poor solubility halt your drug's development
At Synectix Pharmaceutical Solutions Ltd, we are continually expanding our unique platform of drug delivery technologies, which are specifically designed to help facilitate oral and parenteral dosage form development for low solubility, poorly bioavailable compounds.
Working predominantly in the preclinical arena, we understand that drug availability may be very limited. We have adapted all of our systems to allow us to work on milligram quanitites of material, thus enabling you to rapidly and cost effectively evaluate the various formulation options for your molecule without embarking on costly and time consuming projects.
Our technologies can be used to support all stages of preclinical drug development, from developability screening of compounds emerging from the discovery stages through to provision of formulations to support in vivo toxicity testing and pharmacokinetic investigations. In parallel, our processes have been established to allow rapid technology transfer for early phase clinical trials manufacture and supply.
Our technologies are used to:
- Improve poor bioavailability and low solubility by formulating in a solubilised liquid, crystalline nanoparticulate or stabilised amorphous solid formulation
- Overcome poor dissolution / dispersion velocity using our proprietary nanoparticulate processing technology
- Improve sub-optimal release profiles by developing alternatives such as fast dissolving, controlled or modified release dosage forms
- Provide rapid and reliable pre-formulation screening to assess and characterize API and excipients
- Formulate APIs with complex physical or chemical characteristics such as low melting point, hygroscopic or oxidation sensitive
- Reformulating existing pharmaceutical, OTC or Nutraceutical products to extend patent protection or create innovative new line extensions
Read about a typical case study where we have helped a client overcome a formulation challenge (more info)
